About Silexion Therapeutics Ltd.
https://silexion.comSilexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
CEO
Ilan Hadar
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
POLAR ASSET MANAGEMENT PARTNERS INC.
Shares:743.48K
Value:$26.62K
LINDEN ADVISORS LP
Shares:337.5K
Value:$12.08K
ARISTEIA CAPITAL LLC
Shares:236.55K
Value:$8.47K
Summary
Showing Top 3 of 24
About Silexion Therapeutics Ltd.
https://silexion.comSilexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $3.29M ▲ | $-3.26M ▼ | 0% | $2.88 ▲ | $-3.26M ▼ |
| Q2-2025 | $0 | $2.28M ▲ | $-2.5M ▼ | 0% | $-4.32 ▼ | $-2.5M ▼ |
| Q1-2025 | $0 | $1.65M ▼ | $-1.74M ▲ | 0% | $0.26 ▲ | $-1.72M ▲ |
| Q4-2024 | $0 | $1.9M ▼ | $-1.75M ▲ | 0% | $-2.7 ▲ | $-5.84M ▲ |
| Q3-2024 | $0 | $8.04M | $-11.85M | 0% | $-18.31 | $-11.78M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $9.24M ▲ | $11.61M ▲ | $4.64M ▼ | $6.98M ▲ |
| Q2-2025 | $3.47M ▼ | $5.8M ▼ | $5.68M ▼ | $120K ▼ |
| Q1-2025 | $6.15M ▲ | $8.31M ▲ | $5.72M ▼ | $2.59M ▲ |
| Q4-2024 | $1.22M ▼ | $2.86M ▼ | $6.85M ▼ | $-3.99M ▲ |
| Q3-2024 | $1.97M | $3.09M | $7.67M | $-4.58M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.26M ▼ | $-2.84M ▼ | $0 ▲ | $8.62M ▲ | $5.78M ▲ | $-2.84M ▼ |
| Q2-2025 | $-2.5M ▼ | $-2.51M ▼ | $-1K ▲ | $-195K ▼ | $-2.69M ▼ | $-2.51M ▼ |
| Q1-2025 | $-1.74M ▲ | $-2.45M ▲ | $-6K ▼ | $7.43M ▲ | $4.96M ▲ | $-2.46M ▲ |
| Q4-2024 | $-1.75M ▲ | $-2.93M ▼ | $0 ▲ | $2.18M ▼ | $-753K ▼ | $-2.93M ▼ |
| Q3-2024 | $-11.86M | $-2.65M | $-16K | $2.92M | $276K | $-2.67M |
CEO
Ilan Hadar
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
POLAR ASSET MANAGEMENT PARTNERS INC.
Shares:743.48K
Value:$26.62K
LINDEN ADVISORS LP
Shares:337.5K
Value:$12.08K
ARISTEIA CAPITAL LLC
Shares:236.55K
Value:$8.47K
Summary
Showing Top 3 of 24